Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 15;8(10):4490-4498.
eCollection 2016.

The Wnt/β-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment

Qiang Zhang  1 , Xing-Kai Meng  1 , Wan-Xiang Wang  1 , Rui-Ming Zhang  1 , Tong Zhang  1 , Jian-Jun Ren  1
Affiliations

The Wnt/β-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment

Qiang Zhang et al. Am J Transl Res. .

Abstract

β-catenin is a key protein that is encoded by the CTNNB1 gene in the Wnt signaling pathway. This study investigated the associations between β-catenin expression and implications for the efficacy of gemcitabine on pancreatic cancer cells in a three-dimensional (3-D) cancer microenvironment. For low β-catenin expression pancreatic carcinoma cells, the inhibition rates (IRs) for low, middle, and high doses of gemcitabine were 0.615 ± 0.079, 0.691 ± 0.093, and 0.765 ± 0.061, respectively. For the high β-catenin expression pancreatic carcinoma cells, the IRs for the same doses were 0.325 ± 0.072, 0.453 ± 0.075, and 0.537 ± 0.056, respectively. Additionally, the evaluation of β-catenin immunoreactivity in 31 pancreatic cancer patients revealed that the low β-catenin protein expression group had significantly longer overall survival (OS) and disease free survival (DFS) than the high β-catenin protein group (P < 0.05). Overall, β-catenin protein expression levels were significantly correlated to gemcitabine sensitivity in seven pancreatic carcinoma cell lines in the 3-D cancer microenvironment. These data suggest that large-scale clinical studies are warranted to assess the role of the Wnt/β-catenin signaling pathway on β-catenin protein expression and chemosensitivity to gemcitabine in pancreatic cancer.

Keywords: Wnt signaling pathway; chemoresistance; pancreatic carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multicellular spheroids (MCS) model designed to mimic the in-vivo microenvironment. (bars 50 um, original magnification 400 ×). A: Pancreatic cancer cell PANC-1 cultured in traditional 2-D monolayers. B: MCS model of PANC-1 cultured in 3-D culture after 7 days.
Figure 2
Figure 2
β-catenin protein expression in seven cell lines. β-actin was used as a loading control.
Figure 3
Figure 3
Optical density ratio analysis showed that β-catenin protein expression was significantly lower in cells in the Low Expression group than in cells in the High Expression group.
Figure 4
Figure 4
Sensitivity to three concentrations of gemcitabine in seven pancreatic cancer cell lines, showing broad variation in IRs to gemcitabine among the cell lines in the MCS model.
Figure 5
Figure 5
Effect of protein expression on in-vitro sensitivity to gemcitabine. The IRs at each concentration of gemcitabine tested were significantly lower in cells in the High Expression group than in cells in the Low Expression group (P < 0.05).
Figure 6
Figure 6
β-catenin protein immunostaining of formalin-fixed, paraffin-embedded human pancreatic cancer. Illustrative cases are shown: A: Low β-catenin Expression; B: High β-catenin Expression.
Figure 7
Figure 7
Kaplan-Meier analysis of OS and DFS found that the Low Expression group had longer OS and DFS than the High Expression group.
See this image and copyright information in PMC

References

    1. Dimou F, Sineshaw H, Parmar AD, Tamirisa NP, Jemal A, Riall TS. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer. J Gastrointest Surg. 2016;20:93–103. - PMC - PubMed
    1. Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol. 2016;4:315–325. - PMC - PubMed
    1. Che ZM, Jung TH, Choi JH, Yoon DJ, Jeong HJ, Lee EJ, Kim J. Collagen-based co-culture for invasive study on cancer cells-fibroblasts interaction. Biochem Biophys Res Commun. 2006;346:268–275. - PubMed
    1. Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16:967–978. - PMC - PubMed
    1. Jung DB, Yun M, Kim EO, Kim J, Kim B, Jung JH, Wang E, Mukhopadhyay D, Hammond E, Dredge K, Shridhar V, Kim SH. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget. 2015;6:4992–5004. - PMC - PubMed

LinkOut - more resources